M. K. Riaz

Most-cited papers

1. Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma

   T. Wise-Draper, S. Gulati, Sarah Palackdharry, B. Hinrichs +22 more

   2022Clinical Cancer Research160 citations Open access

   Semantic Scholar

   Save

2. High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma

   S. Haque, V. Karivedu, M. K. Riaz, David Choi +7 more

   2018Oral Oncology47 citations Open access

   Semantic Scholar

   Save

3. Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, non-randomized, phase-2 clinical trial

   S. Gulati, McKenzie Crist, M. K. Riaz, V. Takiar +7 more

   2023Clinical Cancer Research25 citations Open access

   Semantic Scholar

   Save

4. Phase 2 trial of adjuvant nivolumab following salvage resection in patients with recurrent squamous cell carcinoma of the head and neck

   J. Leddon, S. Gulati, S. Haque, C. Allen +17 more

   2022Clinical Cancer Research15 citations Open access

   Semantic Scholar

   Save

5. Interim analysis of a single arm phase II study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy

   T. Wise-Draper, S. Haque, A. Steele, S. Desai +7 more

   2019Annals of Oncology2 citations Open access

   Semantic Scholar

   Save